Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
Studies suggest that the continuous use of bevacizumab, a vascular endothelial growth factor inhibitor, may play a crucial role in improving therapy success in patients with metastatic colorectal cancer. This is a case report of a female 60-year-old patient with colon cancer metastases in the liver and lungs refractory to mFOLFOX6 and FOLFIRI given as first and second-line therapy, respectively, who demonstrated a good response to FOLFOXIRI and bevacizumab as third-line therapy. Bevacizumab may be added to first, second and third-line chemotherapy for palliative treatment of metastatic colorectal cancer, and data indicate an increase in patient survival with a good response rate and low toxicity.